It is best framed as an investigational peptide discussed around muscle repair, regeneration, and IGF-1/MGF biology rather than an approved treatment [1] [2] [10]
This mechanism was documented in humans in 1984 by Bowers and confirmed in multiple clinical studies (Nass et al., J Clin Endocrinol Metab 2008)
R., Carr, A., Diener, C., Locey, K
Kim JM, Choi YM, Jung SA, Yang HR
Detoxification of xenobiotics by plants: chemical modification and vacuolar compartmentation
Julio Rosenstock, director of the Dallas Diabetes Research Center, expanded on the results of tirzepatide, explaining that the SURPASS-3 trial showed that it leads to greater time in range